Blog
Retatrutide CAS: 2381089-83-2
Writer： admin Time：2023-07-16 12:41 Browse：℃
Newest GLP-1R Triple Agonist Peptides
Retatrutide (CAS: 2381089-83-2) is under pre-sale for the treatment of type 2 diabetes mellitus, obesity and non-alcoholic fatty liver disease. The drug candidate is administered through subcutaneous route. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a new molecular entity.
Production schedule : 30 days
Alpha Biotech is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men’s health, and musculoskeletal problems.
QQ客服